Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant pseudomonas aeruginosa in an in vitro dynamic biofilm model

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2434-2442

  Lora Tamayo, Jaime ^a,b   Murillo, Oscar ^b   Bergen, Phillip J ^a   Nation, Roger L ^a   Poudyal, Anima ^a   Luo, Xianling ^a   Yu, Heidi Y ^a   Ariza, Javier ^b   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Carbapenem resistant; CDC reactors; Foreign body; Infections; PK PD; Polymyxins

Indexed keywords

CARBAPENEM; COLISTIN; DORIPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BACTERIUM ISOLATION; BIOFILM; BIOFILM REACTOR; CONTROLLED STUDY; DYNAMICS; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PSEUDOMONAS AERUGINOSA; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PSEUDOMONAS INFECTION; TIME;

ANTI-BACTERIAL AGENTS; BIOFILMS; CARBAPENEMS; COLISTIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 84905996379     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku151     Document Type: Article

References (69)

1. Talbot GH, Bradley J, Edwards JE Jr et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
2. Erratum in: Clin Infect Dis 2006; 42: 1065
3. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10×'20 progress- development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
4. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
5. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
6. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67: 351-68.
7. Hauser AR, Jain M, Bar-Meir M et al. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24: 29-70.
8. Papagelopoulos PJ, Mavrogenis AF, Giannitsioti E et al. Management of a multidrug-resistant Pseudomonas aeruginosa infected total knee arthroplasty using colistin. A case report and review of the literature. J Arthroplasty 2007; 22: 457-63.
9. Neut D, Hendriks JG, van Horn JR et al. Pseudomonas aeruginosa biofilm formation and slime excretion on antibiotic-loaded bone cement. Acta Orthop 2005; 76: 109-14.
10. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: 32.
11. Nation RL, Li J.; Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-43.
12. Li J, Nation RL, Turnidge JD et al.; Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
13. Falagas ME, Kasiakou SK.; Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
14. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
15. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
16. Garonzik SM, Li J, Thamlikitkul V et al;. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
17. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56: 4241-9.
18. Plachouras D, Karvanen M, Friberg LE et al.; Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 2009; 53: 3430-6.
19. Bergen PJ, Bulitta JB, Forrest A et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54: 3783-9.
20. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55: 5134-42.
21. Bergen PJ, Li J, Nation RL et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008; 61: 636-42.
22. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrugresistant Pseudomonas aeruginosa at multiple inocula by colistincombined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-95.
23. Poudyal A, Howden BP, Bell JM et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62: 1311-8.
24. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-5.
25. Cai Y, Li R, Liang B et al. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 3998-9.
26. Rodriguez CH, De Ambrosio A, Bajuk M et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010; 4: 164-7.
27. Ketthireddy S, Lee DG, Murakami Y et al. In vivo pharmacodynamics of colistin against Pseudomonas aeruginosa in thighs of neutropenic mice. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract A-4, p. 1. American Society for Microbiology, Washington, DC, USA.
28. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-11.
29. Dudhani RV, Turnidge JD, Nation RL et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65: 1984-90.
30. Owen RJ, Li J, Nation RL et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-7.
31. Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 2005; 102: 915-7.
32. Falagas ME, Kapaskelis AM, Kouranos VD et al. Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs 2009; 69: 1351-61.
33. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002; 8: 881-90.
34. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
35. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
36. Moskowitz SM, Foster JM, Emerson J et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-22.
37. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
38. Zusman O, Avni T, Leibovici L et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013; 57: 5104-11.
39. Herrmann G, Yang L, Wu H et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010; 202: 1585-92.
40. Hengzhuang W, Wu H, Ciofu O et al. In vivo pharmacokinetics/ pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012; 56: 2683-90.
41. Hengzhuang W, Wu H, Ciofu O et al. Pharmacokinetics/ pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011; 55: 4469-74.
42. Pamp SJ, Gjermansen M, Johansen HK et al. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68: 223-40.
43. Haagensen JA, Klausen M, Ernst RK et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007; 189: 28-37.
44. Cai Y, Wang R, Liang BB et al. In-vitro bactericidal activity of colistin against biofilm-associated Pseudomonas aeruginosa and Acinetobacter baumannii. J Hosp Infect 2009; 72: 368-70.
45. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
46. Pena C, Suarez C, Tubau F et al. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-b-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin Microbiol Infect 2007; 13: 1026-9.
47. Pena C, Suarez C, Tubau F et al. Nosocomial outbreak of a noncefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 beta-lactamase. J Clin Microbiol 2009; 47: 2381-7.
48. Clinial and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
49. Doribax (Doripenem For Injection) (Package Insert). Raritan, NJ. Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2007.
50. Li J, Milne RW, Nation RL et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-70.
51. Donlan RM, Piede JA, Heyes CD et al. Model system for growing and quantifying Streptococcus pneumoniae biofilms in situ and in real time. Appl Environ Microbiol 2004; 70: 4980-8.
52. Goeres DM, Loetterle LR, Hamilton MA et al. Statistical assessment of a laboratory method for growing biofilms. Microbiology 2005; 151: 757-62.
53. Parra-Ruiz J, Vidaillac C, Rose WE et al. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010; 54: 4329-34.
54. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-51.
55. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther 2009; 31: 42-63.
56. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 365-440.
57. Montero M, Horcajada JP, Sorli L et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37: 461-5.
58. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62.
59. Gunderson BW, Ibrahim KH, Hovde LB et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonasaeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-9.
60. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
61. Mizuyachi K, Hara K, Wakamatsu A et al. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin 2011; 27: 2261-70.
62. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
63. Bulitta JB, Li J, Poudyal A et al. Quantifying synergy of colistin combinations against MDR Gram-negatives by mechanism-based models. In: Abstracts of the Forty-ninth Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-573, p. 41. American Society for Microbiology, Washington, DC, USA.
64. Ciofu O, Mandsberg LF, Bjarnsholt T et al. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 2010; 156: 1108-19.
65. Hoiby N, Krogh Johansen H, Moser C et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3: 23-35.
66. Tyson GW, Chapman J, Hugenholtz P et al. Community structure and metabolism through reconstruction of microbial genomes from the environment. Nature 2004; 428: 37-43.
67. Jensen PO, Bjarnsholt T, Phipps R et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007; 153: 1329-38.
68. Tanaka G, Shigeta M, Komatsuzawa H et al. Effect of the growth rate of Pseudomonas aeruginosa biofilms on the susceptibility to antimicrobial agents: b-lactams and fluoroquinolones. Chemotherapy 1999; 45: 28-36.
69. Hengzhuang W, Ciofu O, Yang L et al. High b-lactamase levels change the pharmacodynamics of b-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013; 57: 196-204.